. Author manuscript; available in PMC: 2018 Feb 12.

Published in final edited form as: Invest New Drugs. 2016 Dec 21;35(3):290–297. doi: 10.1007/s10637-016-0418-8

Table 5.

Best response per dose level

Dose Level	Evaluable patients, n	Tivantinib, oral dose	Temsirolimus, IV dose	Best Response, n
Dose Level	Evaluable patients, n	Tivantinib, oral dose	Temsirolimus, IV dose	PR	SD	PD
1	7	120 mg BID	20 mg weekly	1	2	4
2	8	240 mg BID	20 mg weekly	0	2	6
3	5	360 mg BID	20 mg weekly	0	2	3
Expansion cohort	7	240 mg BID	20 mg weekly	0	2	5

PR: partial response; SD: stable disease; PD: progressive disease